A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Cancer Of Prostate Cancer of the Prostate Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Cancer Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Amsterdam, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histologically or cytologically confirmed prostate cancer.
Prior chemotherapy regimen for prostate cancer

Exclusion criteria

History of other malignancy in the last 5 years
Major surgery within the past 21 days

Treatment and study plan

YM155

Drug

Sponsors and collaborators

Lead sponsor

Astellas Pharma Inc

Industry

Collaborators

Astellas Pharma US, Inc.

Registry information

Important dates

Study completion: 2007
First posted: Nov 23, 2005
Registry last updated: Jun 7, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed